Cargando…
A case series of serious and unexpected adverse drug reactions under treatment with cariprazine
Reporting of new or unexpected adverse drug reactions of medicines that are subject to additional monitoring (“black triangle” label), such as the antipsychotic drug cariprazine, is of paramount importance to improve pharmacotherapy safety.
Autores principales: | Heck, Johannes, Seifert, Johanna, Stichtenoth, Dirk O., Schroeder, Christoph, Groh, Adrian, Szycik, Gregor R., Degner, Detlef, Adamovic, Ivana, Schneider, Michael, Glocker, Catherine, Rüther, Eckart, Bleich, Stefan, Grohmann, Renate, Toto, Sermin |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8142394/ https://www.ncbi.nlm.nih.gov/pubmed/34084502 http://dx.doi.org/10.1002/ccr3.4084 |
Ejemplares similares
-
COVID-19-Impfung unter Psychopharmakotherapie
por: Seifert, Johanna, et al.
Publicado: (2021) -
Dear Doctor Letters regarding citalopram and escitalopram: guidelines vs real-world data
por: de Bardeci, Mateo, et al.
Publicado: (2022) -
Sex differences in pharmacological treatment of major depressive disorder: results from the AMSP pharmacovigilance program from 2001 to 2017
por: Seifert, Johanna, et al.
Publicado: (2021) -
Pharmacotherapy of 1,044 inpatients with posttraumatic stress disorder: current status and trends in German-speaking countries
por: Reinhard, Matthias A., et al.
Publicado: (2020) -
Galactorrhea during antipsychotic treatment: results from AMSP, a drug surveillance program, between 1993 and 2015
por: Glocker, C., et al.
Publicado: (2021)